

MPR of patients with diabetes (n=10) was compared to those without. Patient age, sex, body surface area (BSA), LV end-diastolic volume (EDV), ejection fraction (EF) and the presence or absence of hypertension and late gadolinium enhancement (LGE) were recorded. A multivariable analysis was performed to determine the contributions of these factors to the MPR.

**Results** Global LV MPR was: 3.07 across all patients, 2.33 for those with diabetes and 3.27 in those without diabetes (p=0.009). Multivariable analysis indicated that diabetes and age were negatively associated with MPR even after adjustment for sex, BSA, LGE, hypertension, LV EF and EDV (p<0.05 for each group).

**Conclusion** In patients with non-obstructive epicardial coronary artery disease, the myocardial perfusion reserve falls with diabetes and increasing age. This is immediately visualisable by used automated in-line perfusion mapping.


024 SPECTRUM AND SIGNIFICANCE OF CMR FINDINGS IN CARDIAC TRANSTHYRETIN AMYLOIDOSIS

<sup>1</sup>Ana Martinez-Naharro, <sup>2</sup>Thomas A Treibel, <sup>2</sup>Amna Abdel-Gadir, <sup>2</sup>Heerajnarain Bulluck, <sup>1</sup>Giulia Zumbo, <sup>1</sup>Daniel S Knight, <sup>1</sup>Tushar Kotecha, <sup>1</sup>Rohin Francis, <sup>1</sup>David Hutt, <sup>1</sup>Tamer Rezk, <sup>2</sup>Stefania Rosmini, <sup>1</sup>Cristina Quarta, <sup>1</sup>Carol J Whelan, <sup>3</sup>Peter Kellman, <sup>1</sup>Julian D Gillmore, <sup>2</sup>James C Moon, <sup>1</sup>Philip N Hawkins, <sup>1</sup>Marianna Fontana. <sup>1</sup>CMR Unit, Royal Free Hospital, University College London, UK; <sup>2</sup>Barts Heart Centre, West Smithfield, London, UK; <sup>3</sup>National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA


10.1136/heartjnl-2017-311399.24

**Background** Cardiac transthyretin amyloidosis (ATTR amyloidosis) is an increasingly recognised cause of heart failure. Cardiovascular magnetic resonance (CMR) with late gadolinium enhancement (LGE) and T1 mapping is emerging as a reference standard for diagnosis and characterisation of cardiac amyloid.


Asymmetric hypertrophy. Sigmoid septal contour (55%)




Asymmetric hypertrophy. Reverse septal contour (24%)



Symmetric hypertrophy (18%)





No LVH (3%)



No LGE

Subendocardial LGE

Transmural LGE



**Abstract 024 Figure 1** Left: four-chamber SSEP cine image in diastole and corresponding late gadolinium enhancement (LGE) images of four patients; asymmetric hypertrophy with sigmoid septal contour and transmural LGE (top); asymmetric hypertrophy with reverse septal contour and transmural LGE (second from top); symmetric hypertrophy pattern and transmural LGE (third from top); left ventricular hypertrophy and subendocardial LGE (bottom). Right top; Kaplan-Meier curve for ECV. Right bottom: four-chamber SSFP cine image in diastole and corresponding LGE images, native T1 maps and ECV maps of these patients, showing no LGE (top), subendocardial LGE (middle) and transmural LGE (bottom).

**Objectives** We used CMR with extracellular volume fraction (ECV) measurement to characterise cardiac involvement in relation to outcome in ATTR amyloidosis.

**Methods** Subjects comprised 263 patients with cardiac ATTR amyloidosis corroborated by grade 2–3  $^{99m}\text{Tc}$ -DPD cardiac uptake, 17 with suspected cardiac ATTR amyloidosis (grade 1  $^{99m}\text{Tc}$ -DPD) and 12 asymptomatic individuals with amyloidogenic transthyretin (TTR) mutations. Fifty patients with cardiac AL amyloidosis acted as disease controls.

**Results** In contrast to AL amyloidosis, asymmetric septal hypertrophy was present in 79% of ATTR patients (70% sigmoid septum and 30% reverse septal curvature), whilst symmetric left ventricular hypertrophy (LVH) was present in only 18%; 3% of patients has no LVH. In patients with cardiac amyloidosis, the pattern of LGE was always typical for amyloidosis (29% subendocardial, 71% transmural) including right ventricular LGE (96%). 65 patients died during follow-up ( $19 \pm 14$  months). ECV independently correlated with mortality and remained independent after adjustment for age, N-terminal pro-brain natriuretic peptide, ejection fraction, E/E' and left ventricular mass index (hazard ratio, 1.164; 95% confidence interval, 1.066–1.271;  $p < 0.01$ ).

**Conclusions** Asymmetric hypertrophy, traditionally associated with hypertrophic cardiomyopathy, is the commonest pattern of ventricular remodelling in ATTR amyloidosis. LGE imaging is typical in all patients with cardiac ATTR amyloidosis. ECV correlates with amyloid burden and provides incremental information on outcome even after adjustment for known prognostic factors.

025

#### DETERMINANTS OF PULMONARY ARTERIAL REMODELLING IN COPD AND IMPLICATIONS FOR RIGHT VENTRICULAR REMODELLING

Jonathan Weir-McCall, Patrick Liu-Shiu-Cheong, Allan D Struthers, Brian J Lipworth, J Graeme Houston. *University of Dundee, UK*

10.1136/heartjnl-2017-311399.25

**Introduction** Pulmonary hypertension is a common complication of chronic obstructive pulmonary disease (COPD). Pulmonary arterial stiffening has been described in COPD both in those with pulmonary hypertension at rest and at exercise. Pulmonary pulse wave velocity (PWV) allows the non-invasive measurement of pulmonary arterial stiffening providing the potential for detection of early pulmonovascular changes before overt pulmonary hypertension sets in, but has not previously been assessed in COPD. The aim of the current study is thus to assess PWV in COPD and its effects on right ventricular (RV) remodelling.

**Methods** 58 participants with COPD underwent pulmonary function tests, six minute walk test, and cardiac MRI, while 21 age and sex matched healthy volunteers underwent cardiac MRI. 32 of the COPD patients underwent a follow-up MRI at 1 year to assess for longitudinal changes. Phase contrast imaging of the main pulmonary artery was performed in order to calculate pulmonary PWV using the flow-area technique.

**Results** Those with COPD demonstrated pulmonary arterial stiffening and pulmonary vascular remodelling with higher pulmonary artery area at end diastole (COPD:  $2.36 \pm 0.56 \text{ cm}^2/\text{m}^{1.7}$  vs. HC:  $2.14 \pm 0.28 \text{ cm}^2/\text{m}^{1.7}$ ,  $p = 0.027$ ), reduced pulsatility (COPD:  $24.9 \pm 8.8\%$  vs. HC:  $30.6\% \pm 11.3\%$ ,  $p = 0.021$ ), reduced PAT (COPD:  $104.0 \pm 22.9 \text{ ms}$  vs. HC:  $128.1 \pm 32.2$

$\text{ms}$ ,  $p < 0.001$ ) and higher PWV (COPD:  $2.62 \pm 1.29 \text{ ms}^{-1}$  vs. HC:  $1.78 \pm 0.72 \text{ ms}^{-1}$ ,  $p = 0.001$ ). Pulmonary PWV was not associated with lung function, exercise capacity or right ventricular parameters. Cardiac remodelling in COPD was instead that of a reduced preload with a lower RV end diastolic volume (COPD:  $53.6 \pm 11.1 \text{ ml}$  vs. HC:  $59.9 \pm 13.0 \text{ ml}$ ,  $p = 0.037$ ) and RV stroke volume (COPD:  $31.9 \pm 6.9 \text{ ml/m}^2$  vs. HC:  $37.1 \pm 6.2 \text{ ml/m}^2$ ,  $p = 0.003$ ). At follow-up those with the stiffest pulmonary arteries (top tertile of PWV) experienced no greater increase in RV mass than those with the lowest stiffness (bottom tertile of PWV),  $p = 0.29$  for difference.

**Conclusion** Pulmonary PWV is elevated in COPD, but does not have any significant association with right ventricular function or functional capacity. In fact remodelling in COPD is that of a reduced preload rather than the expected increased afterload.

## Comparison of Acceleration Algorithms in Whole-Heart Four

026


#### DIMENSIONAL FLOW CARDIOVASCULAR MAGNETIC RESONANCE: TWO-CENTRE, 1.5T, PHANTOM AND IN-VIVO VALIDATION STUDY

<sup>1</sup>Pankaj Garg, <sup>2</sup>Jos JM Westenberg, <sup>2</sup>Pieter J van den Boogaard, <sup>1</sup>Peter P Swoboda, <sup>1</sup>Rahoz Aziz, <sup>1</sup>James RJ Foley, <sup>1</sup>Graham J Fent, <sup>2</sup>FGJ Tyl, <sup>2</sup>L Coratella, <sup>2</sup>Mohammed SM ElBaz, <sup>2</sup>RJ van der Geest, <sup>3</sup>David M Higgins, <sup>1</sup>John P Greenwood, <sup>1</sup>Sven Plein. <sup>1</sup>Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK; <sup>2</sup>Leiden University Medical Centre, Leiden, The Netherlands <sup>3</sup>Philips Healthcare, Guildford, UK

10.1136/heartjnl-2017-311399.26

**Background** Validation of four-dimensional (4D) flow CMR accelerated acquisition methods is needed to make them more robust for clinical applications.<sup>1</sup> Our aim was to compare three widely-used acceleration methods in 4D flow CMR: 4D segmented fast-gradient-echo (4D-turbo-field-echo, 4D-TFE), 4D non-segmented gradient-echo with echo-planar imaging (4D-EPI) and 4D-*k-t* Broad-use Linear Acquisition Speed-up Technique accelerated TFE (4D-*k-t* BLAST).

**Methods** CMR was performed in two institutions on identical 1.5T systems. Acceleration methods were compared in static/



**Abstract 026 Figure 1** Illustration to demonstrate static and pulsatile flow phantom setup.